The emergence of non-albicans Candida species as causes of invasive candidiasis and candidemia

被引：63
作者：
Sobel J.D. [1 ]
机构：
[1] Division of Infectious Diseases, Harper University Hospital, Detroit, MI 48201
来源：
Current Infectious Disease Reports | 2006年 / 8卷 / 6期
关键词：
Voriconazole; Azole; Candida Species; Caspofungin; Posaconazole;
D O I：
10.1007/s11908-006-0016-6
中图分类号：
学科分类号：
摘要：
The last three decades have seen an expanding pool of high-risk patients susceptible to the opportunistic pathogen Candida. Accordingly, a dramatic increase in nosocomial blood stream infections (BSIs) due to Candida spp has been reported throughout the world, starting in tertiary care centers and spreading to community hospitals. This absolute increase in Candida BSIs was accompanied by both an absolute and then a proportional increase in invasive infection caused by reduced fluconazole-susceptible non-albicans Candida spp. Currently, the incidence trend of BSI has stabilized, and Candida albicans remains the most common species causing fungal BSI. Clinicians must be aware of the importance and implications of non-albicans Candida spp when selecting anti-fungal drugs, although most studies have not shown significant outcome differences with use of the various antifungal classes. Copyright © 2006 by Current Science Inc.
引用
收藏
页码：427 / 433
页数：6
相关论文
共 46 条
  • [1] Pappas P.G., Rex J.H., Lee J., Et al., A prospective observational study of candidemia: Epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients, Clin Infect Dis, 37, pp. 634-643, (2003)
  • [2] Morgan J., Global trends in candidemia: Review of reports from 1995-2005, Curr Infect Dis Rep, 7, pp. 429-439, (2005)
  • [3] Hajjeh R.A., Sofair A.N., Harrison L.H., Et al., Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program, J Clin Microbiol, 42, pp. 1519-1527, (2004)
  • [4] Eggimann P., Garbino J., Pittet D., Epidemiology of Candida species infections in critically ill non-immunosuppressed patients, Lancet Infect Dis, 3, pp. 685-702, (2003)
  • [5] Jarvis W.R., Epidemiology of nosocomial fungal infections, with emphasis on Candida species, Clin Infect Dis, 20, pp. 1526-1530, (1995)
  • [6] Wisplinghoff H., Bischoff T., Tallent S.M., Et al., Nosocomial bloodstream infections in US hospitals: Analysis of 24,179 cases from a prospective nationwide surveillance study, Clin Infect Dis, 39, pp. 309-317, (2004)
  • [7] Martin G.S., Mannino D.M., Eaton S., Moss M., The epidemiology of sepsis in the United States from 1979 through 2000, N Engl J Med, 348, pp. 1546-1554, (2003)
  • [8] Gudlaugsson O., Gillespie S., Lee K., Et al., Attributable mortality of nosocomial candidemia, revisited, Clin Infect Dis, 37, pp. 1172-1177, (2003)
  • [9] Mora-Duarte J., Betts R., Rotstein C., Et al., Comparison of caspofungin and amphotericin B for invasive candidiasis, N Engl J Med, 347, pp. 2020-2029, (2002)
  • [10] Trick W.E., Fridkin S.K., Edwards J.R., Et al., Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999, Clin Infect Dis, 35, pp. 627-630, (2002)
12345